Multicenter Prospective Pilot Study Identifying Thrombomodulin as a Potential Biomarker for Neurocognitive Outcomes in Immune Thrombotic Thrombocytopenic Purpura.
Article in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors.
Aaron B BoothbyDivision of Hematology and Oncology, University of Washington, Seattle, WA 98195, USA.ORCID 0000-0001-9566-7809
Michael D EvansClinical and Translational Science Institute, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0001-7449-3993
Shangbin YangSection of Hematology-Oncology, Ohio State University, Columbus, OH 43210, USA.
Senthil SukumarSection of Hematology-Oncology, Baylor College of Medicine, Houston, TX 77030, USA.ORCID 0000-0002-0882-6793
James G ScottDepartment of Psychiatry and Behavioral Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Deirdra R TerrellDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.ORCID 0000-0003-0794-5851
Spero CatalandDivision of Hematology, Department of Medicine, Ohio State University, Columbus, OH, USA.ORCID 0000-0001-8977-6910
Marshall MazepaDivision of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0003-4294-3069
Funding
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UM1TR004405 · NCATS · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar, Damien A Fair · 2023 to 2026
$30.8M
RESEARCH TRAINING IN HEMATOLOGYT32HL007093 · NHLBI · UNIVERSITY OF WASHINGTON · PI Janis L Abkowitz · 1985 to 2026
$13.9M
Life after Recovery in Adult Thrombotic Thrombocytopenic Purpura (TTP): Let's Hear It from the SurvivorsK01HL135466 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI TERRELL, DEIRDRA R · 2017 to 2021
$687k
NCATS NIH HHS UL1 TR002494NCATS NIH HHS UM1 TR004405NHLBI NIH HHS K01 HL135466NHLBI NIH HHS T32 HL007093This study received support from the Answering TTP Foundation, an institutional training grant from the National Institutes of Health, the National Heart, Lung, and Blood Institute, and the National Institutes of Health's National Center for Advancing Tra T32 HL007093, UL1TR002494 and UM1TR004405
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Multicenter Prospective Pilot Study Identifying Thrombomodulin as a Potential Biomarker for Neurocognitive Outcomes in Immune Thrombotic Thrombocytopenic Purpura. · full record | Socratic